To determine the efficacy of Temozolomide defined as progression-free survival at 6 months and safety of Temozolomide when administered orally, once a day for 5 days repeated every 28 days in the treatment of patients with GBM (Glioblas-toma Multiforme) or AA (Anaplastic Astrocytoma) at first relapse. A reference agent procarbazine is included in the study of patients with GBM to verify that objective responses can be obtained using the reference agent.
Showing the most recent 10 out of 563 publications